Article
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Future oncology (London, England) - 1 Dec 2020
Hochmair Maximilian J, Morabito Alessandro, Hao Desiree, Yang Cheng-Ta, Soo Ross A, Yang James C-H, Gucalp Rasim, Halmos Balazs, Märten Angela, Cufer Tanja
Abstract excerpt
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory....
Topics
Join the communities discussing this publication.